1D·

More info: California lawmakers want to cut Medicare coverage for GLP-1s

$NOVO B (-1.35%)
$HIMS (-0.39%)
$LLY (+0%)
$UNH (-0.2%)


- Lawmakers propose cutting Wegovy and Zepbound from Medicaid to reduce $12 billion deficit

- Would save $680 million annually through 2029 if passed

attachment

Source: Bloomberg Law


Novo Nordisk is under investigation by the Spanish Ministry of Health for possible illegal advertising of its hit drug Wegovy. The authorities believe that an online campaign related to Novo could be classified as indirect advertising for a prescription drug, which is prohibited. The website is now offline. Shares fell as much as 2.8% in Copenhagen on Wednesday. (via Bloomberg)

attachment
21
11 Comments

profile image
Very good, was just about to summarize it :), that's the way!
10
profile image
This is the way 👍
The planned cuts are bad news for $HIMS. This could lead to a loss of customers and revenue 👎
1
profile image
@fund_commander123 absolutely not! Top for Hims if it is enforced. The expensive original products will be taken out of the insurance and customers will be more likely to go for the cheaper Hims alternative
6
profile image
@Lupo201 @fund_commander123 That's how I see it too, $HIMS is trying to make treatments and medicines more affordable. As far as GLP1 is concerned, so far it has mainly been personalized, but when that comes, the question of drug price caps will probably come up again. But if people are not covered by Medicare, which is only available to certain people, or by private insurance, they will look for cheaper alternatives. This has enormous potential once the patents expire at the latest.
5
@Lupo201 yes, perhaps I should have read more than just the headline. You're right, of course. Then of course I'm all the happier for my $HIMS position 😅
5
profile image
❤️🚀
1
profile image
The market must have felt very good today...
1
profile image
@Doe I'm not sure if $HIMS is really losing trust here as an American company just because a European company is making claims and desperate to sell its products. Seems more like Robinhood vs Prince John to me 😂. I think the consumer likes what $HIMS is doing and the products should work, I'm curious to see how this develops.
2
Get out with a slight plus at €35 or hold the share? What do you think?
profile image
@MaxGPower $HIMS always hold, what kind of question is that anyway😅
1
Join the conversation